Same protocol. No prescription.
SleepShift vs Somryst:
The honest comparison.
Somryst is the only FDA-cleared digital CBT-I program. After Pear Therapeutics' Chapter 11 in April 2023, Nox Health acquired Somryst at auction and now distributes it exclusively through employer health plans and health systems — not direct to consumers. SleepShift delivers the same 5-component CBT-I protocol direct-to-consumer, with no prescription, no waitlist, and a free 7-day trial.
$0.19/day
annual plan · $69.99/yr
- Full 5-component CBT-I protocol
- Free 7-day trial (card on file, $0 today)
- No prescription required
- Start immediately
- Reviewed by Dr. Candice Seti, Psy.D.
- HSA/FSA eligible
- Cancel anytime
B2B only
via employer plans (Nox Health, since 2023)
- Full 5-component CBT-I protocol (9-week)
- No direct-to-consumer purchase path
- Requires doctor prescription
- Employer enrollment + Rx wait
- FDA De Novo cleared (retained by Nox Health)
- HSA/FSA eligible (when employer-provided)
- Was $899 DTC under Pear · no current DTC price
Feature-by-feature comparison
| Feature | SleepShift | Somryst |
|---|---|---|
| Direct-to-consumer access | Yes — start today | No — B2B only since June 2023 |
| Price | From $0.19/day ($69.99/yr) | Not sold direct to consumers (was $899 under Pear) |
| Prescription required | No | Yes — physician required |
| Wait time | Start today | Employer enrollment + Rx wait |
| CBT-I protocol | Full 5-component | Full 5-component (9-week) |
| FDA status | Not FDA-cleared (wellness) | FDA De Novo cleared (Rx DTx) |
| Free trial | 7-day free trial (card on file, $0 charged) | No trial |
| Clinical reviewer / operator | Dr. Candice Seti, Psy.D. | Nox Health (acquired from Pear, 2023) |
| HSA/FSA eligible | Yes | Yes (when employer-provided) |
| Cancellation | Cancel anytime | Through employer plan |
Somryst pricing and requirements based on publicly available product information. Prices and availability subject to change.
The honest take
What Somryst's FDA clearance actually means
Somryst's FDA De Novo clearance validates one important thing: CBT-I works for chronic insomnia. The FDA reviewed the clinical evidence and concluded the 5-component CBT-I protocol is safe and effective — which is exactly what the peer-reviewed literature has shown since the 1980s.
The FDA clearance is for Somryst as a specific prescription medical device — not for CBT-I as a concept. CBT-I is a published clinical protocol. SleepShift uses the same published protocol, reviewed by Dr. Candice Seti, Psy.D., a Certified Insomnia Treatment Clinician.
Since Pear Therapeutics' Chapter 11 in 2023, Somryst is no longer sold direct to consumers — Nox Health distributes it through employer health plans only. If your employer offers Nox's sleep program and FDA clearance matters to you, that's a fit. If you want immediate direct access to the same evidence-based protocol, SleepShift is the right choice.
Common questions
Is SleepShift as effective as Somryst?
Both deliver the same 5-component CBT-I protocol, which has a 70–80% remission rate in clinical trials. The protocol's effectiveness comes from the components themselves (sleep restriction, stimulus control, cognitive restructuring) — not from FDA clearance. SleepShift is reviewed by Dr. Candice Seti, a Certified Insomnia Treatment Clinician, to ensure clinical fidelity.
Can I just buy Somryst directly?
Not anymore. After Pear Therapeutics filed for Chapter 11 in April 2023, Nox Health acquired Somryst at auction in June 2023 and now distributes it exclusively through employers, health plans, and health systems. There is no direct-to-consumer purchase path — you can only access Somryst if your employer or health plan offers it. SleepShift is direct-to-consumer.
Do I need a doctor to use SleepShift?
No. SleepShift requires no referral, prescription, or doctor visit to start. The intake assessment flags contraindications (like untreated sleep apnea or certain mood disorders) and will advise you to consult a doctor if applicable. For the majority of adults with primary chronic insomnia, you can start immediately.
What is the FDA De Novo clearance for Somryst?
Somryst received FDA De Novo clearance as a prescription digital therapeutic (DTx) for adults 22+ with chronic insomnia. The clearance is retained by Nox Health, the current owner. The FDA designation validates that the CBT-I protocol the device delivers is clinically effective — but the product is only accessible via prescription, and now only through employer-sponsored channels. SleepShift uses the same published CBT-I protocol as a wellness program.
What if I want an FDA-cleared product?
If FDA clearance is your requirement, check whether your employer's benefits include Nox Health's sleep program (which now includes Somryst). If your employer doesn't offer it — or you want immediate access without going through a benefits administrator — SleepShift delivers the same five-component CBT-I protocol direct to you.
Try it free
The same protocol.
Free 7-day trial.
No prescription. No employer plan required. Start with the free 28-question assessment — see your insomnia profile and projected CBT-I plan before committing to anything.
Free 7-day trial · Card on file · Reviewed by Dr. Candice Seti, Psy.D.
SleepShift is a structured wellness program and is not a medical device or FDA-cleared product. This comparison is provided for informational purposes. Product information for Somryst sourced from publicly available materials and may change. SleepShift does not claim equivalence to FDA-cleared medical devices.